AgomAb Therapeutics director buys 14,980 shares
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
AgomAb Therapeutics NV (AGMB) director David R. Epstein purchased 14,980 common shares directly on November 13, 2026, across four reported transactions: 5,000 at $5.99, 20 at $6.00, 5,000 at $5.75 and 4,960 at $6.02 per share. No Rule 10b5-1 plan is reported.
Insider Trade Summary
Net Buyer: 14,980 shares
Net Buy
4 txns
Insider
Epstein David R
Role
Director
Bought
14,980 shs ($89K)
Increase in Position
37.5%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common shares F1 | 5,000 | $5.99 | $30K |
| Purchase | Common shares F1 | 20 | $6.00 | $120.00 |
| Purchase | Common shares F1 | 5,000 | $5.75 | $29K |
| Purchase | Common shares F1 | 4,960 | $6.02 | $30K |
Holdings After Transaction:
Common shares — 54,980 shares (Direct)
Holdings Before and After:
Common shares, 40,000 to 54,980 shares (Direct)
Footnotes (1)
- F1. The common shares may be represented by American Depositary Shares, each of which currently represents one common share.
Key Figures
Shares purchased: 14,980 shares
Purchase: 5,000 shares at $5.99 per share
Purchase: 20 shares at $6.00 per share
+2 more
5 metrics
Shares purchased
14,980 shares
Four direct purchases on November 13, 2026
Purchase
5,000 shares at $5.99 per share
November 13, 2026
Purchase
20 shares at $6.00 per share
November 13, 2026
Purchase
5,000 shares at $5.75 per share
November 13, 2026
Purchase
4,960 shares at $6.02 per share
November 13, 2026
Key Terms
American Depositary Shares
1 terms
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.